Co-expression of PIAS4 and wild-type VHL again showed binding between them and this interaction was lost when wild-type VHL was replaced with VHL containing mutations in the PIAS-binding region (W88S and Y112H).
The relative luciferase activity was significantly inhibited by the co-transfection of miR-24 mimics and the luciferase reporters containing the predicted target regions of BCL2L11 mRNA (Fig. 2B and 2C); while the inhibition was lost when the binding sites in 3′UTR were mutated (Fig. 2B and 2C).
Mutating the Ds phosphorylation sites resulted in a significantly improved binding ability, however, this improved ability was lost when Ft was also not phosphorylated.
We identified an undocumented region 375 385 of DLC1 as the PTB-domain-binding site and the DLC1-tensin2 interaction was lost when this region was removed (Fig. 4B).
In support of this model, KAP1 recruitment to the HCMV genome was lost when the KRAB-binding RBCC domain was deleted (not illustrated).
Interestingly, the ability of Uhrf1 to target Dnmt1 activity to replication foci was lost when Uhrf1 lost both its base-flipping and H3K9me3/me2 binding capacity [100], or its E3 ligase activity [99].
This gel shift was lost when either excess unlabelled competitor DNA probe or STAT3 antibody was added to the binding reactions thus verifying their specificity for STAT3.
Interestingly, this effect was lost when endothelium was removed.
Presumably, the integrity of the substrate binding site is lost when these residues are mutated leading to lower affinity for substrate.
However, the ATGA binding specificity is lost when the two thiophenes are replaced with two furans (DB914), and related compounds DB832, DB934, DB1246, DB1324, DB1579, DB1315, and DB1256, or by two selenophanes (DB1282 and DB1273 with phenyls or pyridines, respectively).
